ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced - PharmiWeb.com

Week 240 data from the BRIGHTE-study of first-in-class fostemsavir continue to show improvement in immunologic response and favourable virologic outcomesLondon, 29 July 2022 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfiz…

Week 240 data from the BRIGHTE-study of first-in-class fostemsavir continue to show improvement in immunologic response and favourable virologic outcomes London, 29 July 2022 ViiV Healthcare, the gl… [+10931 chars]

full article...